Abstract
Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Current Pharmaceutical Design
Title: New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways
Volume: 15 Issue: 14
Author(s): Akira Nishida, Tsuyoshi Miyaoka, Takuji Inagaki and Jun Horiguchi
Affiliation:
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Abstract: Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Export Options
About this article
Cite this article as:
Nishida Akira, Miyaoka Tsuyoshi, Inagaki Takuji and Horiguchi Jun, New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways, Current Pharmaceutical Design 2009; 15 (14) . https://dx.doi.org/10.2174/138161209788168065
DOI https://dx.doi.org/10.2174/138161209788168065 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expansion of Umbilical Cord Blood for Clinical Transplantation
Current Stem Cell Research & Therapy CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets Heme Oxygenase-1 and Iron in Liver Inflammation: A Complex Alliance
Current Drug Targets A Rare Case of Drug-induced Erectile Dysfunction with Adalimumab and Certolizumab Solved after Switch to Ustekinumab in a Crohn's Disease Patient
Current Drug Safety Medicinal Importance, Pharmacological Activities, and Analytical Aspects of Engeletin in Medicine: Therapeutic Benefit Through Scientific Data Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Patents Review in Microencapsulation of Pharmaceuticals Using the Emulsion Solvent Removal Methods
Recent Patents on Drug Delivery & Formulation Commentary
CNS & Neurological Disorders - Drug Targets Nimesulide Apparent Solubility Enhancement with Natural Cyclodextrins and their Polymers
Letters in Drug Design & Discovery Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
Anti-Cancer Agents in Medicinal Chemistry A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research The Role of Glial Cells in Drug Abuse
Current Drug Abuse Reviews The Potential of Allergen Biochips
Recent Patents on Inflammation & Allergy Drug Discovery Occurrence, Structure Elucidation, Biosynthesis, Functions and Synthesis of Sphingadienes
Mini-Reviews in Organic Chemistry Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Antagonists of CCR4 as Immunomodulatory Agents
Current Topics in Medicinal Chemistry Compositions for Treatment of Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Identification of a Novel Glutathione Conjugate of Diclofenac by LTQOrbitrap
Drug Metabolism Letters New Treatments for COPD in the Elderly
Current Pharmaceutical Design